

Pablo Zubiaur

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5339212/publications.pdf>

Version: 2024-02-01

42
papers

609
citations

759055

12
h-index

713332

21
g-index

44
all docs

44
docs citations

44
times ranked

722
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. <i>Pharmaceuticals</i> , 2022, 15, 78. | 1.7 | 8 |
| 2 | Patients'™ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 270. | 1.1 | 3 |
| 3 | Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers. <i>Advances in Therapy</i> , 2022, 39, 1743-1753. | 1.3 | 10 |
| 4 | Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. <i>Pharmaceutics</i> , 2022, 14, 559. | 2.0 | 6 |
| 5 | The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice. <i>Diabetologia</i> , 2022, 65, 490-505. | 2.9 | 9 |
| 6 | Pharmacogenetics of Donepezil and Memantine in Healthy Subjects. <i>Journal of Personalized Medicine</i> , 2022, 12, 788. | 1.1 | 3 |
| 7 | Transmembrane protease serine 2 (<i>TMPRSS2</i>) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity. <i>Life Science Alliance</i> , 2022, 5, e202201396. | 1.3 | 3 |
| 8 | Correction: Transmembrane protease serine 2 (<i>TMPRSS2</i>) rs75603675, comorbidity and sex are the primary predictors of Covid-19 severity. <i>Life Science Alliance</i> , 2022, 5, e202201545. | 1.3 | 0 |
| 9 | Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400Âmg. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 125-136. | 1.1 | 2 |
| 10 | Safety and cardiovascular effects of multipleâ€dose administration of aripiprazole and olanzapine in a randomised clinical trial. <i>Human Psychopharmacology</i> , 2021, 36, 1-12. | 0.7 | 10 |
| 11 | Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. <i>Advances in Therapy</i> , 2021, 38, 1035-1054. | 1.3 | 17 |
| 12 | Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111087. | 2.5 | 12 |
| 13 | Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021, 60, 261-270. | 1.6 | 12 |
| 14 | SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. <i>Journal of Personalized Medicine</i> , 2021, 11, 204. | 1.1 | 19 |
| 15 | Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. <i>Frontiers in Pharmacology</i> , 2021, 12, 660639. | 1.6 | 1 |
| 16 | Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1569-1582. | 1.6 | 11 |
| 17 | Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. <i>Frontiers in Pharmacology</i> , 2021, 12, 711940. | 1.6 | 24 |
| 18 | PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. <i>Journal of Clinical Medicine</i> , 2021, 10, 3772. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1573. | 2.0 | 4 |
| 20 | The pharmacogenetics of treatment with olanzapine. <i>Pharmacogenomics</i> , 2021, 22, 939-958. | 0.6 | 11 |
| 21 | ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112083. | 2.5 | 3 |
| 22 | HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 53-59. | 0.7 | 4 |
| 23 | Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin. <i>Frontiers in Pharmacology</i> , 2021, 12, 718281. | 1.6 | 4 |
| 24 | Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. <i>Pharmaceutics</i> , 2021, 13, 2036. | 2.0 | 8 |
| 25 | Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. <i>Pharmacogenomics Journal</i> , 2020, 20, 235-245. | 0.9 | 10 |
| 26 | Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. <i>Talanta</i> , 2020, 208, 120450. | 2.9 | 43 |
| 27 | Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 236-246. | 1.2 | 7 |
| 28 | Author's Response to: "Letter to the Editor in Response to: "Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administered Orally or Vaginally". <i>Advances in Therapy</i> , 2020, 37, 965-967. | 1.3 | 0 |
| 29 | Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). <i>Clinical and Translational Science</i> , 2020, 13, 1023-1033. | 1.5 | 11 |
| 30 | Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. <i>Pharmacogenomics</i> , 2020, 21, 663-675. | 0.6 | 8 |
| 31 | Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. <i>Advances in Therapy</i> , 2020, 37, 3537-3550. | 1.3 | 16 |
| 32 | The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2051-2062. | 1.1 | 19 |
| 33 | Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. <i>Biomedicines</i> , 2020, 8, 94. | 1.4 | 57 |
| 34 | Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administered Orally or Vaginally. <i>Advances in Therapy</i> , 2019, 36, 2744-2755. | 1.3 | 6 |
| 35 | Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. <i>Clinical Therapeutics</i> , 2019, 41, 1199-1212.e2. | 1.1 | 23 |
| 36 | Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation. <i>Talanta</i> , 2019, 198, 159-168. | 2.9 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Polymorphisms in <i>CYP1A2</i> , <i>CYP2C9</i> and <i>ABCB1</i> affect agomelatine pharmacokinetics. <i>Journal of Psychopharmacology</i> , 2019, 33, 522-531. | 2.0 | 36 |
| 38 | Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2019, 41, 2558-2570.e7. | 1.1 | 31 |
| 39 | Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 321-329. | 1.2 | 39 |
| 40 | Effect of <i>ABCB1</i> C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485. | 1.2 | 51 |
| 41 | Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. <i>Journal of Psychopharmacology</i> , 2018, 32, 1212-1222. | 2.0 | 10 |
| 42 | How to make P-glycoprotein (<i>ABCB1</i> , <i>MDR1</i>) harbor mutations and measure its expression and activity in cell cultures?. <i>Pharmacogenomics</i> , 2018, 19, 1285-1297. | 0.6 | 7 |